Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2018

Open Access 01-12-2018 | Letter

Efficacy of polymyxin B hemoperfusion in and beyond septic shock: is an “endotoxin severity score” needed?

Authors: Patrick M. Honore, David De Bels, Thierry Preseau, Sebastien Redant, Herbert D. Spapen

Published in: Critical Care | Issue 1/2018

Login to get access

Excerpt

Polymyxin B (PMX) is a cationic polypeptide antibiotic which can bind and neutralize endotoxin. Parenteral administration of PMX, however, is associated with substantial nephrotoxicity limiting its clinical use. Immobilizing PMX to polystyrene-derived fibers in a cartridge integrated in a hemoperfusion device therefore represents an elegant method that permits adequate PMX therapy while avoiding systemic toxicity. …
Literature
1.
Nakamura Y, Kitamura T, Kiyomi F, Hayakawa M, Hoshino K, Kawano Y, Yamasaki R, Nishida T, Mizunuma M, Ishikura H, Japan Septic Disseminated Intravascular Coagulation (JSEPTIC DIC) study group, et al. Crit Care. 2017;21:134.CrossRefPubMedPubMedCentral
2.
3.
4.
Marshall JC, Foster D, Vincent JL, Cook DJ, Cohen J, Dellinger RP, Opal S, Abraham E, Brett SJ, Smith T, et al. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis. 2004;190:527–34.CrossRefPubMed
5.
Iba T, Fowler L. Is polymyxin B-immobilized fiber column ineffective for septic shock? A discussion on the press release for EUPHRATES trial. J Intensive Care. 2017;5:40.CrossRefPubMedPubMedCentral
Metadata
Title
Efficacy of polymyxin B hemoperfusion in and beyond septic shock: is an “endotoxin severity score” needed?
Authors
Patrick M. Honore
David De Bels
Thierry Preseau
Sebastien Redant
Herbert D. Spapen
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2018
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-018-2093-y

Other articles of this Issue 1/2018

Critical Care 1/2018 Go to the issue

Research

Resuscitative endovascular balloon occlusion of the aorta performed by emergency physicians for traumatic hemorrhagic shock: a case series from Japanese emergency rooms

Research

Early fibrinogen concentrate therapy for major haemorrhage in trauma (E-FIT 1): results from a UK multi-centre, randomised, double blind, placebo-controlled pilot trial

Review

The role of adrenaline in cardiopulmonary resuscitation

Research

Interventions to prevent hemodynamic instability during renal replacement therapy in critically ill patients: a systematic review

Research

Ventilator-induced lung injury is aggravated by antibiotic mediated microbiota depletion in mice

Research

Bright environmental light improves the sleepiness of nightshift ICU nurses